| Nov 13 |
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
|
| Nov 7 |
Protagonist GAAP EPS of -$0.54 beats by $0.07, revenue of $4.68M beats by $2.87M
|
| Nov 7 |
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
Protagonist Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 5 |
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
|
| Sep 10 |
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
|
| Sep 9 |
Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years
|
| Sep 3 |
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
|
| Aug 6 |
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
|
